Fiona Gupta, MD , our Medical Director and prescribing physician
[Laughing.] But the bottom line is, most skin doesnt need tons of stuff on it
Injection site reactions are more common with amylin analogs, and the dual-mechanism approach means managing two sets of potential adverse effects
That last point matters enormously for postpartum women
Late in 2023 the Food and Drug Administration approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity and a BMI of 30 or over with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol) for use, in addition to a reduced calorie diet and increased physical activity
Zepbound is an FDA-approved, once-weekly injectable GLP-1 medication for chronic weight management, authorized in October 2023